Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 1 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, 2010-11-29 Alpha Recycling in Confirmatory.

Slides:



Advertisements
Similar presentations
Issues of Simultaneous Tests for Non-Inferiority and Superiority Tie-Hua Ng*, Ph. D. U.S. Food and Drug Administration Presented at MCP.
Advertisements

1 Health Warning! All may not be what it seems! These examples demonstrate both the importance of graphing data before analysing it and the effect of outliers.
1 O Guilbaud, MCP2007, July 8-11, Vienna, v.1 Simultaneous Confidence Regions corresponding to Holm’s Step-down MTP (and other CTPs) Olivier Guilbaud.
LSU-HSC School of Public Health Biostatistics 1 Statistical Core Didactic Introduction to Biostatistics Donald E. Mercante, PhD.
FTP Biostatistics II Model parameter estimations: Confronting models with measurements.
Copyright © 2014 by McGraw-Hill Higher Education. All rights reserved.
By Trusha Patel and Sirisha Davuluri. “An efficient method for accommodating potentially underpowered primary endpoints” ◦ By Jianjun (David) Li and Devan.
A new group-sequential phase II/III clinical trial design Nigel Stallard and Tim Friede Warwick Medical School, University of Warwick, UK
Design and analysis of clinical trials MULTIPLE COMPARISONS.
Elementary hypothesis testing
1 A Bayesian Non-Inferiority Approach to Evaluation of Bridging Studies Chin-Fu Hsiao, Jen-Pei Liu Division of Biostatistics and Bioinformatics National.
Hypothesis Testing Steps of a Statistical Significance Test. 1. Assumptions Type of data, form of population, method of sampling, sample size.
Introduction to Hypothesis Testing
Elementary hypothesis testing Purpose of hypothesis testing Type of hypotheses Type of errors Critical regions Significant levels Hypothesis vs intervals.
PSY 1950 Confidence and Power December, Requisite Quote “The picturing of data allows us to be sensitive not only to the multiple hypotheses that.
Chapter 9 Hypothesis Testing.
Adaptive Designs for Clinical Trials
Power and Non-Inferiority Richard L. Amdur, Ph.D. Chief, Biostatistics & Data Management Core, DC VAMC Assistant Professor, Depts. of Psychiatry & Surgery.
Example 10.1 Experimenting with a New Pizza Style at the Pepperoni Pizza Restaurant Concepts in Hypothesis Testing.
Hypothesis Tests and Confidence Intervals in Multiple Regressors
Psy B07 Chapter 1Slide 1 ANALYSIS OF VARIANCE. Psy B07 Chapter 1Slide 2 t-test refresher  In chapter 7 we talked about analyses that could be conducted.
Carl-Fredrik Burman, PhD, Assoc Prof Senior Principal Scientist AstraZeneca R&D Mölndal Multiplicity in a decision-making context.
Multiple testing in high- throughput biology Petter Mostad.
Business Statistics, A First Course (4e) © 2006 Prentice-Hall, Inc. Chap 9-1 Chapter 9 Fundamentals of Hypothesis Testing: One-Sample Tests Business Statistics,
Sections 8-1 and 8-2 Review and Preview and Basics of Hypothesis Testing.
Fundamentals of Hypothesis Testing: One-Sample Tests
Analysis of Clinical Trials with Multiple Outcomes Changchun Xie, PhD Assistant Professor of Biostatistics Division of Biostatistics and Bioinformatics.
Week 8 Fundamentals of Hypothesis Testing: One-Sample Tests
1 Today Null and alternative hypotheses 1- and 2-tailed tests Regions of rejection Sampling distributions The Central Limit Theorem Standard errors z-tests.
Overview Basics of Hypothesis Testing
Essential Statistics in Biology: Getting the Numbers Right
Sample size determination Nick Barrowman, PhD Senior Statistician Clinical Research Unit, CHEO Research Institute March 29, 2010.
Example 10.1 Experimenting with a New Pizza Style at the Pepperoni Pizza Restaurant Concepts in Hypothesis Testing.
Hypothesis Testing Quantitative Methods in HPELS 440:210.
Lecture 7 Introduction to Hypothesis Testing. Lecture Goals After completing this lecture, you should be able to: Formulate null and alternative hypotheses.
STA Statistical Inference
Biostatistics Class 6 Hypothesis Testing: One-Sample Inference 2/29/2000.
Decision-Theoretic Views on Switching Between Superiority and Non-Inferiority Testing. Peter Westfall Director, Center for Advanced Analytics and Business.
Chapter 8 Introduction to Hypothesis Testing ©. Chapter 8 - Chapter Outcomes After studying the material in this chapter, you should be able to: 4 Formulate.
Back to basics – Probability, Conditional Probability and Independence Probability of an outcome in an experiment is the proportion of times that.
DSBS Discussion: Multiple Testing 28 May 2009 Discussion on Multiple Testing Prepared and presented by Lars Endahl.
1 Controlling False Positive Rate Due to Multiple Analyses Controlling False Positive Rate Due to Multiple Analyses Unstratified vs. Stratified Logrank.
Copyright © 2010, 2007, 2004 Pearson Education, Inc Section 8-2 Basics of Hypothesis Testing.
Correct decisions –The null hypothesis is true and it is accepted –The null hypothesis is false and it is rejected Incorrect decisions –Type I Error The.
Statistics for Managers Using Microsoft Excel, 4e © 2004 Prentice-Hall, Inc. Chap 8-1 Chapter 8 Fundamentals of Hypothesis Testing: One-Sample Tests Statistics.
Economics 173 Business Statistics Lecture 4 Fall, 2001 Professor J. Petry
Multiple Testing Matthew Kowgier. Multiple Testing In statistics, the multiple comparisons/testing problem occurs when one considers a set of statistical.
Statistical Methods for Identifying Differentially Expressed Genes in Replicated cDNA Microarray Experiments Presented by Nan Lin 13 October 2002.
Information Technology and Decision Making Information Technology and Decision Making Example 10.1 Experimenting with a New Pizza Style at the Pepperoni.
August, 2002MCP A General Multiplicity Adjustment Approach and Its Application to Evaluating Several Independently Conducted Studies Qian Li and Mohammad.
Copyright © 1998, Triola, Elementary Statistics Addison Wesley Longman 1 Assumptions 1) Sample is large (n > 30) a) Central limit theorem applies b) Can.
Marshall University School of Medicine Department of Biochemistry and Microbiology BMS 617 Lecture 6 –Multiple hypothesis testing Marshall University Genomics.
URBDP 591 A Lecture 16: Research Validity and Replication Objectives Guidelines for Writing Final Paper Statistical Conclusion Validity Montecarlo Simulation/Randomization.
Copyright© 1998, Triola, Elementary Statistics by Addison Wesley Longman 1 Testing a Claim about a Mean: Large Samples Section 7-3 M A R I O F. T R I O.
1 השוואות מרובות מדדי טעות, עוצמה, רווחי סמך סימולטניים ד"ר מרינה בוגומולוב מבוסס על ההרצאות של פרופ' יואב בנימיני ופרופ' מלכה גורפיין.
A Parametrized Strategy of Gatekeeping, Keeping Untouched the Probability of Having at Least One Significant Result Analysis of Primary and Secondary Endpoints.
Chapter 15 Analysis of Variance. The article “Could Mean Platelet Volume be a Predictive Marker for Acute Myocardial Infarction?” (Medical Science Monitor,
Estimating the False Discovery Rate in Genome-wide Studies BMI/CS 576 Colin Dewey Fall 2008.
Confidence Intervals for Means
Assumptions For testing a claim about the mean of a single population
Statistical Core Didactic
Review and Preview and Basics of Hypothesis Testing
Multiple Endpoint Testing in Clinical Trials – Some Issues & Considerations Mohammad Huque, Ph.D. Division of Biometrics III/Office of Biostatistics/OPaSS/CDER/FDA.
Testing a Claim About a Mean:  Known
Multiplicity Testing Procedure Selection in Clinical Trials Rachael Wen Ph.D JSM 2018 of 8.
Subscript and Summation Notation
Command Terms
Covering Principle to Address Multiplicity in Hypothesis Testing
David Edwards and Jesper Madsen Novo Nordisk
Presentation transcript:

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 1 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Alpha Recycling in Confirmatory Clinical Trials Unifies, Simplifies, Extends many common MTPs Olivier Guilbaud Senior Principal Scientist AstraZeneca R&D, Södertälje, Sweden

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 2 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Outline Background Splitting, Recycling, Adding, (parts of alpha) Graphs and Default Graphs for MTPs Rejection Algorithm Holm’s MTP for groups of Hs, and a problem to discuss Improvements through extensions of the Default Graph Summary, and further results: (Simultaneous Confidence regions, CTP-formulation of MTPs)

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 3 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Background: Regulatory environment Citation from EMEA/CPMP’s (2002) Points to Consider on Multiplicity Issues in Clinical Trials : “ … multiplicity can have a substantial influence on the rate of false positive conclusions …” ”As a general rule it can be stated that control of the family-wise type-I error rate in the strong sense … is a minimal prerequisite for confirmatory claims”

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 4 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Background: Multiple Confirmatory Comparisons Several Efficacy Variables Several Tolerability Variables Several Comparators (e.g. Placebo, Active 1, Active 2, …) Several Doses Delta-Noninferiority / Superiority / Delta-Superiority Several Subgroups/Kinds of Subjects Several kinds of Administration (e.g. once daily, twice daily, …) Confirmatory: Pre-specified family of multiple comparisons (i.e. statistical tests). Risk of getting any ”false positive” result/conclusion is   (no matter how many or which H 0 s are true – Strong Control)

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 5 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Background: Abbreviations/Terminology MTP : Multiple Testing Procedure MCP : Multiple Comparison Procedure FWER : Family-Wise Error Rate (type-I errors) = Pr[at least 1 true H i in the Family is rejected by the MTP] (to be controlled to be   in the strong sense)  , no matter how many, or which, H i s in the family are true In contrast to the weak sense (old) :  , if all H i s in the family are true

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 6 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Background: brief refresher about three basic MTPs Three basic MTPs for Family {H 1, H 2, H 3 } based on raw p-values p 1, p 2, p 3 Holm MTP (1979) p (1)   /3, p (2)   /2, p (3)   /1 Fixed-Sequence MTP (old) p 1  , p 2  , p 3   Fallback MTP (2003/2005) weights w 1, w 2, w 3 p 1  w 1 , p 2  (w 2 +) , p 3  (w 3 +)  Now, to the Alpha-Recycling framework

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 7 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Two articles in Statistics in Medicine, February 2009 Only this now

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 8 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Idea: Splitting and Recycling test-mass (= part of  ) Bonferroni: split of  Fixed-Sequence: recycling of  Combination of split & recycling of  Throughout: Raw p-value available for each null hypothesis H

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 9 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Idea: Adding test-mass from different paths Parallel-gatekeeping MTP: 2 graphs for same MTP Default graph Important for rejection Algorithm Its sequences reflect the possible rejection paths

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 10 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Idea: Adding test-mass from different paths Fallback MTP for 3 Hs: 2 graphs for same MTP Default graph Important for rejection Algorithm Its sequences reflect the possible rejection paths

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 11 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Idea: Adding test-mass from different paths Holm’s MTP for 3 Hs: 2 graphs for same MTP Default graph Important for rejection Algorithm Its sequences reflect the possible rejection paths

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 12 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Rejection Algorithm - based on Default-Graph Seqs This MTP controls (in the strong sense) the FWER to be   ! Step 1. For each ”first” H in Sequences, (a) add-upp test mass from ”its” Sequences (b) test H at this added-up level If nothing is rejected, then Stop; otherwise: Reduce Sequences by deleting all rejected H from Sequences, and go to Step 2 with remaining reduced Sequences Step r = 2, 3, …. For each ”first” H in remaining reduced Sequences, (a) add-upp test mass from ”its” Sequences (b) test H at this added-up level If nothing is rejected, then Stop; otherwise: Reduce Sequences by deleting all rejected H from Sequences, and go to Step r + 1 with remaining reduced Sequences

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 13 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Comments number of sequences can be increased (no restriction) length of sequences can be increased (no restriction) if not all sequences contain all Hs, then improvements are possible (by increasing length of relevant sequences) interpretability of MTP is important (also when improvements are considered)

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 14 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, A refresher – Bonferroni & Holm for groups of Hs Step1: Bonferroni-version as above Step2: If one group is entirely rejected, but not the other, then try again in the other at increased level  Bonferroni for 2 groups of 2 Hs, with Fixed-Seq testing within group  /2 Holm for 2 groups of 2 Hs, with Fixed-Seq testing within group:  /  1

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 15 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Problem to discuss with your neighbour Bonferroni for 2 groups of 2 Hs, with Fixed-Seq testing within group  /2 (is already in default-graph form): Extend sequences of default graph to get recycling improvement equivalent to Holm for 2 groups of 2 Hs, with Fixed-Seq testing within group  /2

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 16 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Recent Example discussed by FDA statisticians Confirmatory family with 4 null hypotheses : H1H1 H2H2 H3H3 H4H4 ww (1-w)  

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 17 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Recent Example discussed by FDA statisticians Alpha-recycling applied to show Non-inf & Superiority for Primary & Secondary Variables H1H1 H2H2 H3H3 H4H4 ww (1-w)   Basic version H1H1 H2H2 H3H3 ww (1-w)  H1H1 H4H4 Reformulation in Recycling terms Very easy to test with rejection algorithm ! But why not recycle also after the last H in each sequence ?

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 18 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Recent Example discussed by FDA statisticians Alpha-recycling applied to show Non-inf & Superiority for Primary & Secondary Variables - Simple improvement ImprovementReformulation in Recycling terms H1H1 H2H2 H3H3 ww (1-w)  H1H1 H4H4 H3H3 H2H2 H4H4 H1H1 H2H2 H3H3 H4H4 ww  Very easy to test with rejection algorithm ! This improved MTP is ”  -exhaustive” ! May be questioned by some (not me)!

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 19 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Sequences can be extended/added for more rejections Improved Fallback MTP for 3 Hs: 2 graphs for same MTP Default graph This improved MTP is ”  -exhaustive” !

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 20 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Sequences can be extended/added for more rejections Improved Parallel-gatekeeping : 2 graphs for same MTP Default graph This improved MTP is ”  -exhaustive” !

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 21 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, XXX example: 2 primary & 2 second vars, 2 age stata  Original proposal Simple improvement possible (  Holm instead of Bonf after H 8 ): Add sub-seq (11, 12) to Default-graph sequences ending with (9, 10) Add sub-seq (9, 10) to Default-graph sequences ending with (11, 12)  /  /  /  /  /  /  /  /8 Default graph Reformulation in Recycling terms to show strong control of FWER

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 22 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Compact notation for MTP in XXX example  Original proposal Compact notation for this recycling MTP (B here is Bonf-operator): B(H 1 B(H 2, H 3 ), H 4 B(H 5, H 6 )) H 7 H 8 B(H 9 H 10, H 11 H 12 ) Can be expanded (using certain rules) to 8 sequences of Hs above  /  /  /  /  /  /  /  /8 Default graph Reformulation in Recycling terms

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 23 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, YYY example: 3 doses vs. 0, 1 primary & 1 second var  /4 Reformulation in Recycling terms Default graph Basic version  /2 Idea: To give lowest dose a chance if at least 1 of the 2 larger doses works for the primary variable

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 24 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, YYY example – Improvement  /4 Reformulation in Recycling terms Default graph Improvement 1  /2 Increases level for H 5 and H 6 if H 3 and/or H 4 are rejected

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 25 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, YYY example – Improvement Improvement 2 1/2  Gives H 1 or H 2 a (Holm-type) second opportunity to be rejected if not rejected initially  /4  /8  /4 Reformulation in Recycling terms Default graph  /

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 26 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Summary, and further results Easy to formulate (cf. Closed-Testing Pocedures) Easy to perform (even manually) Easy to calculate multiplicity-adjusted p-values (algorithm similar to that for rejections) Easy to obtain weights of Bonferroni test for any intersection hypothesis H I of corresponding CTP (useful for contruction of Conf regions) Easy to construct new MTPs (for new problems) Unifies many common MTPs Compact algebraic notation available (to describe and derive default graphs)

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 27 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Corresponding Simultaneous Confidence Regions ??? Holm MTP (1979) p (1)   /3, p (2)   /2, p (3)   /1 Fixed-Sequence MTP (old) p 1  , p 2  , p 3   Fallback MTP (2003/2005) weights w 1, w 2, w 3 p 1  w 1 , p 2  (w 2 +) , p 3  (w 3 +)  Solution in JASA 1999 Open until 2007 Three basic MTPs for Family {H 1, H 2, H 3 } based on raw p-values p 1, p 2, p 3

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 28 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Corresponding Simultaneous Confidence Regions !!! Amazing : Simultanously presented at MCP 2007 in Vienna 28 years after Holm (1979) Extensions and Relations Confidence regions require weights that can be obtained directly from rejection algorithm of recycling approach

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 29 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Alternative formulation of basic MTPs as CTPs Basic MTPs as Closed-Testing Procedures for Family {H 1, H 2, H 3 } based on raw p-values Holm MTP (1979) p (1)   /3, p (2)   /2, p (3)   /1 Fixed-Sequence MTP (old) p 1  , p 2  , p 3   Fallback MTP (2003/2005) weights w 1, w 2, w 3 p 1  w 1 , p 2  (w 2 +) , p 3  (w 3 +) 

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 30 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Holm – Closed-Test formulation Reject H i iff each H I with i  I is rejected by weighted Bonf-test that rejects an H I =  k  I H k iff p k   w k (I) for some k  I ( weights: w k (I)  0,  k  I w k (I)  1 ) H1H1 H2H2 H3H3 H 12 H 13 H 23 H 123 E.g.: H 1 is rejected by Holm iff each H 123, H 12, H 13, and H 1 is rejected by its weighted Bonf-test

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 31 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Fixed-Sequence – Closed-Test formulation Reject H i iff each H I with i  I is rejected by weighted Bonf-test that rejects an H I =  k  I H k iff p k   w k (I) for some k  I ( weights: w k (I)  0,  k  I w k (I)  1 ) H1H1 H2H2 H3H3 H 12 H 13 H 23 H 123 E.g.: H 1 is rejected by F-S iff each H 123, H 12, H 13, and H 1 is rejected by its weighted Bonf-test, i.e. iff p 1  

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 32 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Fallback – Closed-Test formulation (2005) Reject H i iff each H I with i  I is rejected by weighted Bonf-test that rejects an H I =  k  I H k iff p k   w k (I) for some k  I ( weights: w k (I)  0,  k  I w k (I)  1 ) H1H1 H2H2 H3H3 H 12 H 13 H 23 H 123 E.g.: H 1 is rejected by Fallback iff each H 123, H 12, H 13, and H 1 is rejected by its weighted Bonf-test, i.e. iff p 1   w 

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 33 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Weights for intersection H I s in XXX example  Original proposal The CTP formulation involves = 4095 different H I =  k  I H k. But the  w k (I) for k  I to be used in the Bonf-test of a H I =  k  I H k can easily be obtained from”first” H i s remaining after deleting all indexes in I c from seq’s. E.g. with I = {1, 5, 11}, what are  w 1 (I),  w 5 (I),  w 11 (I) ?  /  /  /  /  /  /  /  /8 Default graph Reformulation in Recycling terms

Proprietary and Confidential © AstraZeneca 2009 FOR INTERNAL USE ONLY 34 O Guilbaud, FMS+Cramér Society, AZ-Södertälje, Outline Background Splitting, Recycling, Adding, (parts of alpha) Graphs and Default Graphs for MTPs Rejection Algorithm Holm’s MTP for groups of Hs, and a problem to discuss Improvements through extensions of the Default Graph Summary, and further results: (Simultaneous Confidence regions, CTP-formulation of MTPs)